Bristol-Myers Squibb

YTD

ALL

Trade Bristol-Myers Squibb 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMY

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies.

CEO

Christopher S. Boerner

CEOChristopher S. Boerner

Employees

32,500

Employees32,500

Headquarters

Princeton, New Jersey

HeadquartersPrinceton, New Jersey

Founded

1933

Founded1933

Employees

32,500

Employees32,500

BMY Key Statistics

Market cap

126.46B

Market cap126.46B

Price-Earnings ratio

13.55

Price-Earnings ratio13.55

Dividend yield

4.08%

Dividend yield4.08%

Average volume

13.53M

Average volume13.53M

High today

$62.07

High today$62.07

Low today

$61.40

Low today$61.40

Open price

$61.63

Open price$61.63

Volume

2.01M

Volume2.01M

52 Week high

$68.64

52 Week high$68.64

52 Week low

$42.52

52 Week low$42.52

Stock Snapshot

Bristol-Myers Squibb(BMY) stock is priced at $61.91, giving the company a market capitalization of 126.46B. It carries a P/E multiple of 13.55 and pays a dividend yield of 4.08%.

On 2026-09-25, Bristol-Myers Squibb(BMY) stock moved within a range of $61.40 to $62.07. With shares now at $61.91, the stock is trading +0.8% above its intraday low and -0.3% below the session's peak.

Trading volume for Bristol-Myers Squibb(BMY) stock has reached 2.01M, versus its average volume of 13.53M.

The stock's 52-week range extends from a low of $42.52 to a high of $68.64.

BMY News

TipRanks 4h

Bristol-Myers Squibb: Pipeline Uncertainties and Limited IPF Upside Lead Flynn to Reiterate Sell Rating and Maintain $40 Price Target

Bristol-Myers Squibb, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn from Morgan Stanley maintained a Sell r...

TipRanks 22h

BMY’s Lung Cancer Combo Study Completion Adds Quiet Support to Its Immuno-Oncology Pipeline

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Bristol-Myers Squibb Co. (BMY) has completed a Phase 1 study in China f...

The Motley Fool 1d

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

...

Analyst ratings

58%

of 31 ratings

Buy

35.5%

Hold

58.1%

Sell

6.5%

People also own

Based on the portfolios of people who own BMY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.